TrialRevista de la Facultad de Ciencias Medicas (Cordoba, Argentina)2021

Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome

Marcelo Iastrebner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.